Altria Group (MO)
Consumo básico / Tabaco y nicotina
A highly profitable nicotine oligopoly (operating margin ~47%, extremely capital-light) in structural decline: cigarette volume is falling ~10%/year and the e-vapor business (NJOY) ran into an ITC exclusion order. At ~$68 (forward P/E ~12x, well below the consumer staples band) with a 5-year base case of ~$83 (+4%/year price, +11% including the dividend at a ~5.8% yield): Undervalued — the discount reflects real risk, with the return sustained almost entirely by cash.
- Price
- $67.89
- Intrinsic value (5y, base)
- $83
- Total annual return (5y)
- 10.5%
- Status (nominal)
- Undervalued
- Margin of safety
- +22%
The essentials
- A highly profitable nicotine oligopoly (operating margin ~47%, capex ~1% of revenue) but in structural decline: cigarette volume is falling ~10%/year, only partially offset by price/mix.
- The e-vapor business (NJOY) ran into an ITC exclusion order (patent infringement) that generated ~$2.1bn of non-cash impairments in 2025; oral nicotine (on! pouches, already 56.9% of the oral category) is the portfolio's only genuine growth driver.
- Trades at a forward P/E of ~12x, well below the quality-staples band (16-22x) and Philip Morris International (~22-23x) — the discount reflects litigation of large nominal magnitude (RICO, antitrust, NPM adjustments) and decline risk; the dividend (~5.8% yield, targeted for progressive growth) accounts for most of the return.
Intrinsic value — two valuation methods
Total return at 5 years: 10.5%/year = 4.0% appreciation + 6.5% dividend. The target price ($83) is ex-dividend; the $24 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $106 · Multiples $87) exceeds the market price ($68).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $68 trades ~22.1% below its value discounted to today (~$87); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — Infravalorado: the target price ($83) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$57.
Thesis
The business
Altria is a highly profitable nicotine oligopoly (operating margin ~47%, extremely capital-light) in structural decline: cigarette volume is falling sharply, and the e-vapor segment (NJOY) ran into an ITC exclusion order that generated significant impairments in 2025. The only genuine growth driver is oral nicotine (on! pouches, +11% volume), which is not yet enough to offset the decline in the core business.
The valuation
Valued by P/E on normalized net income (direct equity, no EV bridge): at $68 (forward P/E ~12x, well below the 16-22x band of a quality consumer staple and Philip Morris International's ~22-23x) the base case projects essentially flat net income (~$8bn) — margin expansion and the mix shift toward Oral offset nearly all of the volume decline — with a disciplined exit multiple at the floor of the band (16x, given the erosion of the moat). That yields ~$83/share over five years.
The margin of safety
It trades at a real discount to value, though short of the required margin of safety. The total return (~+10%, mostly the dividend at a ~5.8% yield) falls in the method's average-return range. The discount to the quality-staples band reflects real risk — litigation, volume decline, the NJOY setback — and is not entirely free, but it also does not require any further collapse of the business to justify it. Verdict: Undervalued.
What to watch
The central disconfirming factor is volume: if the decline in cigarettes (−10.0% in 2025) accelerates and price/mix stops offsetting it, earnings — currently holding at ~$8bn — enter genuine decline. Also worth watching: the resolution of the ITC appeal on NJOY, the outcome of the antitrust class action certified in February 2026, and whether the discount category (31.8% share) keeps gaining ground over premium brands.
Educational / informational. Does not constitute investment advice.